CRISPR Therapeutics (NASDAQ:CRSP) Stock Rating Upgraded by StockNews.com
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report released on Friday. CRSP has been the subject of a number of other reports. Citigroup dropped their price target on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research […]
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report released on Friday. CRSP has been the subject of a number of other reports. Citigroup dropped their price target on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research […]
